Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
RESEARCH TOOLSreports
Holding BMRN?
Track your performance easily
BMRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$67.75 - $99.56
Previous Close$70.11
Volume1.51M
Average Volume (3M)1.74M
Market Cap
$13.23B
Enterprise Value$13.09B
Total Cash (Recent Filing)$1.22B
Total Debt (Recent Filing)$1.09B
Price to Earnings (P/E)52.9
Beta0.56
Next Earnings
Oct 29, 2024EPS Estimate
$0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.32
Shares Outstanding190,382,822
10 Day Avg. Volume1,186,483
30 Day Avg. Volume1,742,515
Standard Deviation0.09
R-Squared0.03
Alpha0.00139
Financial Highlights & Ratios
Price to Book (P/B)2.52
Price to Sales (P/S)5.11
Price to Cash Flow (P/CF)27.80
P/FCF Ratio34.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.06
Enterprise Value/Gross Profit6.87
Enterprise Value/Ebitda31.33
Forecast
1Y Price Target
$104.57Price Target Upside49.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering25
BioMarin Pharmaceutical News
PremiumCompany Announcements
BioMarin Pharmaceutical Projects Strong Growth Through 2034Bulls Say, Bears Say
Bulls Say
Intellectual PropertyBMRN's solid intellectual property position in both EU and US could result in significant royalties.
Market PositionBMN-333 is anticipated to help BMRN maintain a leading position and regain market share.
Stock ValuationThere is upside potential for the stock valuation given the current trading levels.
Bears Say
CompetitionThe convenience of TransCon CNP, which is a weekly subcutaneous injection, could be a key competitive advantage as compared to Voxzogo which is a daily subcutaneous injection.
Market ShareWe see new competitors reducing Vox US market share in achondroplasia over time, from peak 36% in 2026 to 22% in 2033.
Stock PressureTransCon CNP’s potential impact to Voxzogo’s commercial share will likely continue to put pressure on the stock.
---
Ownership Overview
0.96% Insiders
34.53% Mutual Funds
0.33% Other Institutional Investors
41.77% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $67.75 and its highest was $99.56 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
Currently, no data Available
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Oct 29, 2024 which is in 10 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Aug 05, 2024. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.358 by $0.192.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is $0.53.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 190,382,830 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.55 in its last earnings report, beating expectations of $0.358. Following the earnings report the stock price went up 7.953%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Among the largest hedge funds holding BioMarin Pharmaceutical’s share is PRIMECAP Management Co. It holds BioMarin Pharmaceutical’s shares valued at 2B.
---
BioMarin Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$104.57 (49.15% Upside)
$104.57 (49.15% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 81%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 30.4%
Last 30 Days ▲ 30.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.90%
12-Months-Change
Fundamentals
Return on Equity
5.10%
Trailing 12-Months
Asset Growth
7.68%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BMRN Company Deck
---
BMRN Earnings Call
Q2 2024
0:00 / 0:00
---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Month Forecast
Average Price Target
$104.57
▲(49.15% Upside)
Technical Analysis
Best Analysts Covering BMRN
1 Year
1 Year Success Rate
24/48 ratings generated profit
1 Year Average Return
-1.62%
reiterated a buy rating last month
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.62% per trade.
---